BS_S9929Z8B
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- overall_survival_months
- 80.35479632063074
- age_years
- 4.663
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.651
- ALLOGRAFT_REJECTION+0.643
- INTERFERON_GAMMA_RESPONSE+0.632
- IL6_JAK_STAT3_SIGNALING+0.621
- INFLAMMATORY_RESPONSE+0.620
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- TNFA_SIGNALING_VIA_NFKB+0.547
- COAGULATION+0.526
- ANGIOGENESIS+0.507
- APICAL_SURFACE+0.451
Top 10 suppressed
- MYC_TARGETS_V1-0.590
- OXIDATIVE_PHOSPHORYLATION-0.570
- MYC_TARGETS_V2-0.505
- E2F_TARGETS-0.462
- DNA_REPAIR-0.431
- UNFOLDED_PROTEIN_RESPONSE-0.414
- G2M_CHECKPOINT-0.407
- PROTEIN_SECRETION-0.397
- MITOTIC_SPINDLE-0.261
- ADIPOGENESIS-0.121
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_W97QQYKQ | Ganglioglioma | — | 0.967 |
| 2 | MNG663 | — | — | 0.952 |
| 3 | TCGA-77-8131-01A-11R-2247-07 | — | cohortSQ1 | 0.950 |
| 4 | BS_3H71BH6Q | Ganglioglioma | — | 0.949 |
| 5 | SRR1431345 | GTEX | — | 0.946 |
| 6 | BS_PJPGVD62 | Ependymoma NOS | — | 0.945 |
| 7 | SJEPD001506_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.942 |
| 8 | BS_PJPGVD62 | EPN | EPN Tumor | 0.941 |
| 9 | BS_T55Y4Z0Y | low-grade glioma | — | 0.941 |
| 10 | SRR1797296 | — | cohortMD2 | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.651 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.643 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.632 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.621 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.620 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.547 | Inavolisib | — uncovered |
| COAGULATION | 0.526 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.507 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.451 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.444 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.443 | Idelalisib | — uncovered |
| COMPLEMENT | 0.416 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.406 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.402 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.369 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.362 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.353 | Inavolisib | — uncovered |
| APOPTOSIS | 0.351 | Idelalisib | — uncovered |